Vendor Intelligence Report: Yongkang Nuoao Trading Co

Executive summary

Across 9 Finnrick lab tests, Yongkang Nuoao Trading Co records 7 passes and 2 failures, an overall pass rate of 78%. The lab record is not the pattern of a pure fake-peptide shop, but it is too uneven for a simple green light. Retatrutide is the better-sampled product and the one with the most important failures: the issue is fill control, not merely whether the peptide is present. Tirzepatide looks cleaner on the public pass/fail line, but the evidence is still thin and becomes less reassuring under stricter fill-accuracy grading.

The buyer-facing problem is traceability. Most Finnrick-tested vials lacked batch IDs, and a vendor-commissioned Janoshik Tirzepatide report lists the batch as Unknown. That means a COA can show that Nuoao had a real sample tested without proving that the vial in hand is from the tested lot. For Retatrutide especially, the report treats Nuoao as a possible real-peptide source that still demands lot-level verification before anyone relies on label quantity.

The infrastructure findings add a separate risk layer. A peptidetr.com contact-page redirect exposed a Shop910 merchant login, and the platform’s own Chinese copy advertises restricted-goods storefront tooling, including AB redirect and Cloak features. The active payment notice is crypto-only, while dormant card and PayPal paths remain in the site bundle, leaving buyers with weaker recourse if fulfillment or substitution goes wrong.

Identity work found one Nuoao sales footprint split across Yongkang, Shenzhen, Vivian, Yamy, Facebook, TikTok discovery pages, and B2B listings, but did not resolve the underlying legal structure. The full dossier is therefore most useful for buyers deciding whether Nuoao is acceptable for a specific GLP-1 product, not for anyone looking for a simple safe/unsafe badge.

Inside the full report:

• Appendix A laboratory data with per-product pass/fail rates and methodology-divergence charts for both tested products
• Retatrutide fill-control analysis, including the February 2026 outlier events
• Shop910 platform evidence, storefront redirect artifacts, and payment-state analysis
• Entity and channel map covering Yongkang, Shenzhen, Nuoao Peptide, Vivian, Yamy, Facebook, and B2B listings
• Janoshik report #73811 assessment and batch-traceability review
• Open leads and dead ends for Chinese registry pulls, Alibaba storefront checks, phone OSINT, and sister-storefront image pivots

Risk assessment

• Retatrutide fill-control risk — high: Retatrutide is 8 tests, 6 pass / 2 fail, current 77.13%; field-level results include severe over-label fills in February 2026.
• Cloaking and payment-evasion infrastructure risk — high: All products: peptidetr.com runs on Shop910, whose live merchant page advertises Cloak and AB redirect tooling for restricted-goods stores.
• Batch traceability risk — medium: All products: 8 of 9 independently tested vials lacked batch IDs; the vendor-commissioned Janoshik report also lists batch as Unknown.
• Crypto-only buyer-recourse risk — medium: All products: site notice says only cryptocurrency is available due to restrictions, eliminating normal card or PayPal chargeback paths.
• Brand-authenticity and channel-confusion risk — medium: All products: Yongkang, Shenzhen, Vivian, and Yamy identities overlap, while no official-channel or authorized-reseller list surfaced.
• Tirzepatide evidence-depth and fill-certainty risk — medium: Tirzepatide has only 1 Finnrick test, 1 pass / 0 fail, current 79.6%; the vendor COA has batch Unknown, leaving lot-level certainty thin.